Singapore Venture Capital Report 2025 — The Exit Nobody Builds For

Southeast Asian venture has an asymmetric problem, and naming it precisely matters more than the usual narrative about market potential.

The input side works. Capital is available from regional funds, global funds with local teams, corporate investors, sovereign vehicles and family offices. Companies get funded through several rounds, and the domicile and structuring apparatus described in the Singapore Venture Capital Report 2024 is genuinely world-class.

The output side does not. A venture investment is only a return when it becomes cash, and the routes available are narrow:

A local listing faces a liquidity problem examined below, which is structural rather than a matter of regulation or effort.

A foreign listing is available to a small number of companies with sufficient scale, and carries cost, disclosure and index-inclusion difficulties that make it viable only at the top end.

A trade sale is the dominant route, and it depends on a limited universe of acquirers — regional conglomerates, global technology companies and a handful of larger regional platforms. Their appetite is set by their own circumstances, not by the quality of what is for sale.

A secondary sale of the position to another investor has grown and remains a partial answer, per the Secondaries Market Report 2023.

The structural consequence is the report's core point:

A venture ecosystem is a pipeline with an entrance and an exit. Building the entrance without the exit produces a growing inventory of unrealised positions, and no amount of capital at the front end fixes a constriction at the back.

The mismatch that makes this expensive is timing. A venture fund has a fixed life — typically ten years. A market that takes fifteen years to develop deep exit routes will see good companies held by funds that must sell before the routes exist. The return is damaged by the calendar rather than by the businesses.

Why a small listing venue stays small

The liquidity problem deserves careful development, because the intuitive remedies do not work and understanding why prevents repeating them.

What an issuer wants from a listing venue:

• A price that reflects the business, which requires enough participants forming views.
• Liquidity for shareholders, so early investors and employees can sell without moving the price.
• Index inclusion, which brings passive demand.
• And analyst coverage, which sustains attention and information flow.

What an investor wants:

• Enough companies to construct a portfolio.
• Enough trading to enter and exit at reasonable cost.
• And enough coverage to analyse them economically.

The circularity is the problem:

1. Few issuers means few investors bother to build local capability.
2. Few investors means poor liquidity and weak pricing.
3. Poor liquidity and weak pricing deter issuers, who list elsewhere or stay private.
4. Return to step one.

Why the obvious remedies fail:

Lowering listing requirements brings smaller and weaker issuers, which worsens the venue's average quality and deters the institutional investors whose participation would create liquidity. It increases issuer count and reduces investor interest, which is the wrong trade.

Subsidising listing costs addresses a real but minor barrier. Cost is not why a company lists elsewhere — pricing and liquidity are.

Mandating domestic institutional allocation creates captive demand, which produces trading volume without price discovery. An investor who must buy is not forming a view.

Market-making support genuinely helps at the margin and does not solve the underlying participation problem.

Liquidity begets liquidity, and the reverse is equally true. A venue below the threshold cannot bootstrap by lowering standards, because the participants it needs are precisely the ones that standards attract.

What does work, slowly: a small number of large, high-quality domestic listings that give institutions a reason to build coverage. The venue is made by its best issuers, not by its issuer count — which means the policy lever is retaining the few companies large enough to anchor it, not attracting the many that are not.

A narrow buyer universe

Trade sale dependency deserves explicit treatment because its risk profile differs from a listing route in ways that matter for underwriting.

Who actually buys venture-backed companies in the region:

• Global technology companies, whose regional acquisition appetite depends on their own strategy, valuation and regulatory environment — none of which is connected to the target's quality.
• Regional conglomerates, which are numerous but historically acquire selectively and often at conservative valuations.
• Larger regional technology platforms, a small group whose own capital position determines their appetite.
• Private equity, which requires the business to be profitable or near it — a filter that excludes much of the venture portfolio.
• And occasionally a competitor, in consolidations.

Why this concentration matters:

Demand is correlated across the whole universe. When global technology valuations fall, acquisition appetite falls across every category of buyer simultaneously. The exit window closes for everyone at once, which is the same structure as the funding-availability concentration in the US Venture Capital Report 2014.

Negotiating position is weak. A seller facing three plausible buyers has materially less leverage than one facing a competitive listing process, and the buyers know the alternatives.

And a listing provides a valuation floor that trade sale does not. A company that can credibly list has an alternative; one that cannot is negotiating against nothing.

The practical consequence for portfolio construction:

In a trade-sale-dependent market, the exit assumption is a bet on someone else's acquisition strategy. It should be underwritten explicitly — who would buy this, why, and what has to be true for them to be buying at all.

The useful diligence question is not whether a company could be acquired but which specific acquirers would want it, and what determines their appetite. That answer is researchable and it is frequently not researched.

Fund life against market clock

The timing mismatch is the most underweighted structural problem and it damages returns from companies that are performing well.

The arithmetic:

• A fund has roughly ten years, sometimes extendable to twelve or thirteen.
• Capital deploys over the first three to five.
• So an investment made in year four has six years to reach an exit.
• If the market's exit routes mature in fifteen years, that investment will be realised through whatever route exists in year ten — which may be a secondary sale at a discount or a trade sale into a thin market.

Why this is different from ordinary exit timing risk:

• In a developed market, the routes exist and the question is conditions. A fund can wait for a better window, and windows recur.
• In a developing market, the route itself may not exist yet. Waiting does not help if the thing being waited for is a decade away.

The consequences, all observable:

• Returns are compressed by time, per the multiple-versus-annualised arithmetic in the Private Equity Report 2012. A company returning four times over twelve years produces a modest annualised return.
• Managers face pressure to sell into poor conditions, because the fund life is contractual and the market is not.
• And the pressure is known to buyers, which weakens price further.

The structural responses that have emerged:

• Longer fund lives — twelve or fourteen years at inception rather than ten with extensions.
• Continuation vehicles, per the Secondaries Market Report 2019, moving assets into a new structure with fresh time and fresh capital.
• Evergreen and permanent capital vehicles, which remove the deadline entirely, per the Private Credit Report 2013's treatment of the same problem in lending.
• And sovereign or family capital, which is genuinely long-dated and does not face the constraint.

The last is where the region has a real structural advantage — the concentration of long-horizon wealth described in the Singapore Investment Report 2020 is exactly the capital type this problem requires.

What state capital can and cannot do

Public capital has been deployed extensively across the region's venture ecosystem, and separating its effective uses from its ineffective ones is analytically useful well beyond this market.

What it does well:

Funds companies that private capital will not. Deep technology with long development timelines, capital-intensive hardware, and sectors where the domestic market is too small to attract global funds. This is a genuine market failure and public capital addresses it directly.

Builds the supporting apparatus. Research institutions, technology transfer, talent programmes and physical infrastructure are public goods that no individual firm will fund.

Anchors first-time funds. A new manager cannot raise without a cornerstone investor, and public capital taking that role creates managers who then raise privately. This is one of the higher-return uses and it is often undervalued because the return accrues to the ecosystem rather than to the programme.

Provides genuinely patient capital, which is exactly what the fund-life problem above requires.

What it cannot do:

Create demand. The constraint at the exit is a shortage of buyers, and no amount of supply-side funding manufactures an acquirer. Public capital can fund a company to the point of sale; it cannot produce someone to sell it to.

Substitute for market discipline. A company sustained by programme funding beyond the point where private investors would support it consumes capital and talent that would otherwise be reallocated.

And it cannot manufacture the liquidity a listing venue needs, for the mandated-allocation reason above — captive demand produces volume without price discovery.

Public capital is effective on the supply side of a venture ecosystem and structurally unable to fix the demand side. The exit problem is a demand problem, which is why funding programmes have not resolved it and will not.

The strongest available public lever on the exit side is regulatory and structural rather than financial: making the listing venue work for the small number of anchor issuers, ensuring cross-border transaction approval is efficient, and removing frictions in secondary transfers.

Domicile is not an ecosystem

A recurring measurement error deserves restating, since it distorts nearly every published figure about this market.

Singapore is the domicile of choice for regional companies and funds for reasons that are entirely rational: legal certainty, contract enforcement, tax treaty coverage, dispute resolution and investor familiarity. The Singapore Venture Capital Report 2024 develops this in detail.

The consequence for statistics:

• Investment "into Singapore" frequently means investment into a Singapore holding company whose operations, customers and employees are elsewhere in the region.
• So the country-level figures overstate Singapore's operating economy and understate the markets where the business actually is.
• And the region's figures are correspondingly distorted, with activity attributed to a jurisdiction chosen for its legal system.

Why this matters for the exit analysis specifically:

• A Singapore-domiciled holding company with Indonesian operations faces the Indonesian market's exit conditions, not Singapore's.
• The acquirer universe is determined by the operating market, not the domicile.
• And a listing decision depends on where the business is understood, which is rarely where it is incorporated.

The practical correction is to analyse by operating market and to treat domicile as a legal fact rather than an economic one. Both are disclosable — company filings state the operating subsidiaries — and the distinction changes the answer to almost every question about this market.

What an allocator could act on

Underwrite the exit explicitly, not the market opportunity. Name the plausible acquirers, establish what determines their appetite, and check whether that appetite correlates with everything else in the portfolio.

Treat listing venue liquidity as self-reinforcing. A venue below the participation threshold cannot bootstrap by lowering standards, so assess it by its anchor issuers rather than its issuer count.

Match fund life to market maturity. A ten-year vehicle in a market whose exit routes mature in fifteen produces poor annualised returns from good companies, and the deadline is known to every buyer.

Prefer structures without a contractual selling deadline where the market's routes are still developing — longer fund lives, continuation vehicles, or genuinely permanent capital.

Read public capital as supply-side only. It funds companies and anchors managers effectively and cannot manufacture the acquirers who eventually pay for them.

Analyse by operating market, not domicile. Holding company jurisdiction determines the legal framework and nothing about the exit conditions, which are set where the business actually operates.

What 2025 established

• Capital formation and exit capacity are separate problems, and only the first has been solved.
• Liquidity is self-reinforcing, so a small venue cannot attract issuers by relaxing standards.
• Trade sale dependency narrows and correlates the exit route, closing it for everyone simultaneously.
• Fixed fund life against a developing market damages returns from companies that are performing.
• State capital works on supply and cannot address demand, which is where the constraint sits.